XML 77 R66.htm IDEA: XBRL DOCUMENT
v3.25.2

Paragon Option Agreements - Narrative (Details) $ in Thousands |  |  | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Apr. 28, 2025 USD ($) | Mar. 18, 2025 USD ($) | Jun. 30, 2025 USD ($) | Jun. 30, 2025 USD ($) employee vote | Dec. 31, 2024 USD ($) | Jun. 30, 2025 USD ($) | Dec. 31, 2026 | Dec. 31, 2025
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Research and development | [1] |  |  | $ 12,081 |  |  | $ 22,708 |  |
License Agreement Terms | Paragon Option Agreements |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Number of employees overseeing and coordinating the project | employee |  |  |  |  | 2 |  |  |  |
Paragon Therapeutics | Paragon Option Agreements |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Accounts payable and other current liabilities |  |  |  | 5,200 | $ 5,200 |  | 5,200 |  |
Paragon Therapeutics | Paragon Option Agreements | Forecast |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Percent of outstanding shares |  |  |  |  |  |  |  | 1.00% | 1.00%
Paragon Therapeutics | License Agreement Terms | Paragon Option Agreements |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Number of employees overseeing and coordinating the project | employee |  |  |  |  | 2 |  |  |  |
Number of votes | vote |  |  |  |  | 1 |  |  |  |
Option agreement termination period, maximum contractual period |  |  |  |  | 30 days |  |  |  |
Expiration period |  |  |  |  | 30 days |  |  |  |
Termination period |  |  |  |  | 30 days |  |  |  |
Research and development |  |  |  | $ 5,019 |  |  | $ 13,033 |  |
Paragon Therapeutics | License Agreement Terms | CR-001 | Paragon Option Agreements |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Non-refundable milestone payments |  |  | $ 22,000 |  |  |  |  |  |
Milestone payment |  | $ 2,500 |  |  |  |  |  |  |
Percent reduction to royalty payment due to invalid patent |  |  |  |  | 30.00% |  |  |  |
Termination period due to breach of contract |  |  |  |  | 60 days |  |  |  |
Sublicense agreement period |  |  |  |  | 30 days |  |  |  |
Paragon Therapeutics | License Agreement Terms | CR-002 | Paragon Option Agreements |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Non-refundable milestone payments |  |  | $ 46,000 |  |  |  |  |  |
Paragon Therapeutics | License Agreement Terms | CR-003 | Paragon Option Agreements |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Non-refundable milestone payments |  | $ 46,000 |  |  |  |  |  |  |
WuXi Biologics Ireland Limited | Cell Line License Agreement |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  | $ 150 |  |  |
Percent of net sales, royalty payment (less than) |  |  |  |  |  | 1.00% |  |  |
Option agreement, termination period |  |  |  |  |  |  | 6 months |  |
Option agreement termination period due to breach of contract |  |  |  |  |  |  | 60 days |  |
Option agreement termination period due to failure to pay |  |  |  |  |  |  | 30 days |  |
[1] | Includes related party amount of $6,292 and $15,069 for the three and six months ended June 30, 2025, respectively.

X
- Definition Asset Acquisition, Maximum Aggregate Milestone Payments + References No definition available. + Details
Name: | cbio_AssetAcquisitionMaximumAggregateMilestonePayments
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Maximum Aggregate, Milestone Payments 1 + References No definition available. + Details
Name: | cbio_AssetAcquisitionMaximumAggregateMilestonePayments1
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Number Of Employees Overseeing And Coordinating Research Project + References No definition available. + Details
Name: | cbio_AssetAcquisitionNumberOfEmployeesOverseeingAndCoordinatingResearchProject
Namespace Prefix: | cbio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Number Of Votes, Option Agreement + References No definition available. + Details
Name: | cbio_AssetAcquisitionNumberOfVotesOptionAgreement
Namespace Prefix: | cbio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Option Agreement Expiration Period + References No definition available. + Details
Name: | cbio_AssetAcquisitionOptionAgreementExpirationPeriod
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Option Agreement Sublicense Agreement Period + References No definition available. + Details
Name: | cbio_AssetAcquisitionOptionAgreementSublicenseAgreementPeriod
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Option Agreement Termination Period + References No definition available. + Details
Name: | cbio_AssetAcquisitionOptionAgreementTerminationPeriod
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Option Agreement Termination Period, Breach Of Contract + References No definition available. + Details
Name: | cbio_AssetAcquisitionOptionAgreementTerminationPeriodBreachOfContract
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Option Agreement Termination Period, Maximum Contractual Period + References No definition available. + Details
Name: | cbio_AssetAcquisitionOptionAgreementTerminationPeriodMaximumContractualPeriod
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Royalty Percent Paid, Reduction Due To Invalid Patent + References No definition available. + Details
Name: | cbio_AssetAcquisitionRoyaltyPercentPaidReductionDueToInvalidPatent
Namespace Prefix: | cbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Class Of Warrants Or Rights, Percent Of Outstanding Shares + References No definition available. + Details
Name: | cbio_ClassOfWarrantsOrRightsPercentOfOutstandingShares
Namespace Prefix: | cbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option Agreement, Royalty Payment, Percent Of Net Sales + References No definition available. + Details
Name: | cbio_OptionAgreementRoyaltyPaymentPercentOfNetSales
Namespace Prefix: | cbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option Agreement, Termination Period + References No definition available. + Details
Name: | cbio_OptionAgreementTerminationPeriod
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option Agreement, Termination Period, Breach Of Contract + References No definition available. + Details
Name: | cbio_OptionAgreementTerminationPeriodBreachOfContract
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option Agreement, Termination Period, Failure To Pay + References No definition available. + Details
Name: | cbio_OptionAgreementTerminationPeriodFailureToPay
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + References No definition available. + Details
Name: | us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | cbio_LicenseAgreementAxis=cbio_ParagonOptionAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_ParagonTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cbio_CR001Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cbio_CR002Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cbio_CR003Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_WuXiBiologicsIrelandLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | cbio_LicenseAgreementAxis=cbio_CellLineLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |